Apollon Wealth Management LLC Sells 6,642 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Apollon Wealth Management LLC cut its stake in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK) by 38.8% during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 10,497 shares of the company’s stock after selling 6,642 shares during the quarter. Apollon Wealth Management LLC’s holdings in Takeda Pharmaceutical were worth $149,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. EverSource Wealth Advisors LLC grew its holdings in shares of Takeda Pharmaceutical by 38.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 3,082 shares of the company’s stock valued at $43,000 after purchasing an additional 859 shares during the last quarter. Headlands Technologies LLC bought a new stake in shares of Takeda Pharmaceutical during the 2nd quarter valued at approximately $59,000. Hexagon Capital Partners LLC grew its holdings in shares of Takeda Pharmaceutical by 34.3% during the 3rd quarter. Hexagon Capital Partners LLC now owns 4,419 shares of the company’s stock valued at $63,000 after purchasing an additional 1,129 shares during the last quarter. Blue Trust Inc. grew its holdings in shares of Takeda Pharmaceutical by 74.0% during the 2nd quarter. Blue Trust Inc. now owns 5,480 shares of the company’s stock valued at $76,000 after purchasing an additional 2,330 shares during the last quarter. Finally, Ridgewood Investments LLC bought a new stake in shares of Takeda Pharmaceutical during the 2nd quarter valued at approximately $89,000. 9.17% of the stock is owned by institutional investors.

Takeda Pharmaceutical Stock Down 0.7 %

NYSE:TAK opened at $13.53 on Tuesday. The firm’s 50 day simple moving average is $14.22 and its 200 day simple moving average is $13.84. The company has a debt-to-equity ratio of 0.64, a current ratio of 1.28 and a quick ratio of 0.77. Takeda Pharmaceutical Company Limited has a one year low of $12.57 and a one year high of $15.08. The company has a market cap of $43.05 billion, a PE ratio of 23.33, a P/E/G ratio of 0.26 and a beta of 0.54.

Takeda Pharmaceutical Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.